|
1
|
Kameda H, Fujii T, Nakajima A, Koike R,
Sagawa A, Kanbe K, Tomita T, Harigai M and Suzuki Y: Japan College
of Rheumatology subcommittee on the guideline for the use of
methotrexate in patients with rheumatoid arthritis. Japan College
of Rheumatology guideline for the use of methotrexate in patients
with rheumatoid arthritis. Mod Rheumatol. 29:31–40. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Gaulard P, Swerdlow SH, Harris NL,
Sundström C and Jaffe ES: Other iatrogenic
immunodeficiency-associated lymphoproliferative disorders. In: WHO
classification of tumours of haematopoietic and lymphoid tissues.
Revised 4th edition. Swerdlow SH, Campo E, Harris NL, et al
(eds.): IARC press, Lyon, pp462-464, 2017.
|
|
3
|
Ichikawa A, Arakawa F, Kiyasu J, Sato K,
Miyoshi H, Niino D, Kimura Y, Takeuchi M, Yoshida M, Ishibashi Y,
et al: Methotrexate/iatrogenic lymphoproliferative disorders in
rheumatoid arthritis: Histology, Epstein-Barr virus, and clonality
are important predictors of disease progression and regression. Eur
J Haematol. 91:20–28. 2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Antunes AA, Nesrallah LJ and Srougi M:
Non-Hodgkin lymphoma of the bladder. Int Braz J Urol. 30:499–501.
2004.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Alaggio R, Amador C, Anagnostopoulos I,
Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D,
Calaminici M, et al: The 5th edition of the World Health
Organization Classification of Haematolymphoid Tumours: Lymphoid
Neoplasms. Leukemia. 36:1720–1748. 2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Peyrade F, Jardin F, Thieblemont C, Thyss
A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi
O, et al: Attenuated immunochemotherapy regimen (R-miniCHOP) in
elderly patients older than 80 years with diffuse large B-cell
lymphoma: A multicentre, single-arm, phase 2 trial. Lancet Oncol.
12:460–468. 2011.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Tokuhira M, Saito S, Suzuki K, Higashi M,
Momose S, Shimizu T, Mori T, Kimura Y, Amano K, Okamoto S, et al:
Clinicopathological features of clinical methotrexate-related
lymphoproliferative disorders. Leuk Lymphoma. 60:2508–2515.
2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kurita D, Miyoshi H, Ichikawa A, Kato K,
Imaizumi Y, Seki R, Sato K, Sasaki Y, Kawamoto K, Shimono J, et al:
Methotrexate-associated Lymphoproliferative disorders in patients
with rheumatoid arthritis: Clinicopathologic features and
prognostic factors. Am J Surg Pathol. 43:869–884. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Yamakawa N, Fujimoto M, Kawabata D, Terao
C, Nishikori M, Nakashima R, Imura Y, Yukawa N, Yoshifuji H, Ohmura
K, et al: A clinical, pathological, and genetic characterization of
methotrexate-associated lymphoproliferative disorders. J Rheumatol.
41:293–299. 2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ohsawa M, Aozasa K, Horiuchi K and
Kanamaru A: Malignant lymphoma of bladder. Report of three cases
and review of the literature. Cancer. 72:1969–1974. 1993.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Simpson RH, Bridger JE, Anthony PP, James
KA and Jury I: Malignant lymphoma of the lower urinary tract. A
clinicopathological study with review of the literature. Br J Urol.
65:254–260. 1990.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Bates AW, Norton AJ and Baithun SI:
Malignant lymphoma of the urinary bladder: A clinicopathological
study of 11 cases. J Clin Pathol. 53:458–461. 2000.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ogihara K, Kosaka T, Kikuchi E, Hongo H,
Mikami S and Oya M: Spontaneous regression of Epstein-Barr
virus-positive primary diffuse large cell B-cell lymphoma of the
urinary bladder after the cessation of enzalutamide. Clin
Genitourin Cancer. 14:e215–e218. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Simpson WG, Lopez A, Babbar P and Payne
LF: Primary bladder lymphoma, diffuse large B-cell type: Case
report and literature review of 26 cases. Urol Ann. 7:268–72.
2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Tokuhira M, Saito S, Okuyama A, Suzuki K,
Higashi M, Momose S, Shimizu T, Mori T, Anan-Nemoto T, Amano K, et
al: Clinicopathologic investigation of methotrexate-induced
lymphoproliferative disorders, with a focus on regression. Leuk
Lymphoma. 59:1143–1152. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Inui Y, Matsuoka H, Yakushijin K, Okamura
A, Shimada T, Yano S, Takeuchi M, Ito M, Murayama T, Yamamoto K, et
al: Methotrexate-associated lymphoproliferative disorders:
Management by watchful waiting and observation of early lymphocyte
recovery after methotrexate withdrawal. Leuk Lymphoma.
56:3045–3051. 2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Tokuhira M, Tamaru JI and Kizaki M:
Clinical management for other iatrogenic
immunodeficiency-associated lymphoproliferative disorders. J Clin
Exp Hematop. 59:72–92. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Al-Sarayfi D, Brink M, Chamuleau MED,
Brouwer R, van Rijn RS, Issa D, Deenik W, Huls G, Mous R, Vermaat
JSP, et al: R-miniCHOP versus R-CHOP in elderly patients with
diffuse large B-cell lymphoma: A propensity matched
population-based study. Am J Hematol. 99:216–222. 2024.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Lontos K, Tsagianni A, Msaouel P, Appleman
LJ and Nasioudis D: Primary urinary tract lymphoma: Rare but
aggressive. Anticancer Res. 37:6989–6995. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Tilly H, Morschhauser F, Sehn LH,
Friedberg JW, Trněný M, Sharman JP, Herbaux C, Burke JM, Matasar M,
Rai S, et al: Polatuzumab vedotin in previously untreated diffuse
large B-cell lymphoma. N Engl J Med. 386:351–363. 2022.PubMed/NCBI View Article : Google Scholar
|
